Background
Introduction
The importance of complete resection of contrast-enhancing tumor in patients with malignant gliomas has been highlighted by several studies [1, 2] . The precise definition of the early postoperative resection status in high-grade gliomas (HGG) is crucial for further treatment planning, e.g. delineation of the radiation field in radiotherapy or surgical re-evaluation if larger residual tumor is present.
Magnetic resonance imaging (MRI) represents the state-of-the-art technique for brain tumor imaging. T1-and T2-weighted sequences provide information on glioma size and localization as well as additional insights on secondary phenomena, i.e. edema, bleeding, necrosis and signs of increased intracranial pressure [3, 4] . In the early postoperative setting after brain tumor surgery, MRI is the imaging modality of choice to verify the resection status. However, the time window for imaging is restricted, because reactive tissue changes normally start to evolve after 48-72 hours.
Many studies have demonstrated the value of [5] [6] [7] [8] and definition of the optimal biopsy site whereas MRI changes may be unspecific and exceed true tumor boundaries (3) (4) (5) . Additionally, malignant high-grade gliomas can present without contrast enhancement and may thereby be underestimated by MRI [5, [8] [9] [10] . In contrast, amino acid tracer uptake even in non-solid, infiltrative parts of gliomas has been demonstrated [11, 12] . Moreover, [
18 F]FET-PET offers a superior differentiation between tumor tissue and reactive changes as it does not accumulate in inflammatory or reactive processes [13, 14] . It improves tumor recurrence detection and results in a better definition of target volumes prior to radiation therapy [15] [16] [17] .
In this study we investigated the value of early post-operative [ 18 F]FET-PET to assess the resection status in comparison to intra-operative findings as well as MRI.
Patients and Methods

Patients
Twenty five consecutive patients (16 males, 9 females; mean age, 62±14 y [range, 26-78 years]) with suspected primary HGG were prospectively enrolled in this study. Tumor surgery was performed in all subjects using dedicated neuro-navigation software (iPlan 3.0; BrainLab, Feldkirchen; Germany), in eloquent localizations with intraoperative neuromonitoring by somatosensory evoked potentials (SSEP) and motor evoked potentials (MEP). Tumor tissue was removed using the cavitron ultrasonic surgical aspirator (CUSA, Valleylab Boulder, CO, USA) device and specimens for histopathologic diagnosis were obtained from the central parts of the tumor. No carmustine wafers were introduced into the resection cavity. All patients underwent pre-and post-operative [ 
Imaging protocols
The PET studies were performed prior to and after (mean, 3±2 days; median, 2 days) the resection using a dedicated ECAT EXACT HR+ PET scanner ( Ã , DWI with ADC map and 3D T1+Gd for navigation sequences were acquired.
After resection (mean; 1±1 day; median; 1 day), axial T1±Gd and subtraction, T2 FLAIR and T2
Ã sequences were obtained. Follow-up MRI and/or PET scans were performed at intervals of three months or at clinical suspicion of tumor recurrence/progression.
Data analysis
PET: Pre-operative scans served as reference for post-operative imaging. Analysis was performed by visual comparison (B.K., C.L.) of both data sets. Focal [
18 F]FET uptake in the primary tumor region higher than background was considered positive for tumor tissue. MRI: All images were analyzed independently by an experienced neuroradiologist who was blinded to the PET data. Residual tumor was defined as previously described [18] .
Histopathology and Immunohistochemistry
All tumor samples were histologically assessed and graded using standard hematoxylin and eosin (H&E) sections (3-4 μm) according to the 2007 World Health Organisation criteria [19] . The astrocytic origin of the tumors was confirmed by positive immunoreaction for the glial fibrillary acidic protein (GFAP 1:200, Dako, Glostrup, Denmark). Oligodendroglial features were assured by the distinct pattern of microtubule-associated protein 2 immunoreactivity (MAP2 1:250, Dako, Glostrup, Denmark).
Results
Tumor characteristics
All patients showed contrast-enhancing brain tumors in pre-operative MRI. Histopathology confirmed HGG in 21/25 patients: 18/25 had glioblastoma, 3 patients anaplastic oligoastrocytoma. 2 patients suffered from grade II oligodendroglioma, the remaining 2 from grade II astrocytoma. Information on the patients´characteristics is provided in Table 1 .
[ 18 
F]FET-PET imaging results in comparison to the reference standards
Intra-surgical assessment of resection status using 5-ALA postulated complete resection in 17/ 25 [76%) of cases. Post-operative MRI was concordantly negative for remaining tumor in 17/ 25 subjects. In one patient, it was negative despite intra-operative concern for incomplete resection, in another case it detected contrast enhancement highly suspicious for vital tumor in contrast to a negative surgical report. In 12/25 patients (48%) post-operative [ 18 F]FET-PET revealed no remaining tumor tissue consistent with the two other reference modalities. An example is given in Fig 1. In the remaining 13 subjects (52%), focally increased [
18 F]FET uptake suspicious for tumor remnants was observed. 6 out of those 13 cases (46%) were consistent with both MRI and 5-ALA and therefore considered true positive. In 7 patients, PET revealed discordant findings. In one subject (#15), both PET and 5-ALA were positive for residual tumor whereas MRI did not indicate tumor tissue. This patient died only three months after brain surgery. In another patient (#23), both imaging modalities raised the concern for viable tumor despite negative intra-surgical assessment. This patient deceased five months later. In the remaining 5 patients (#7, 16, 18, 21, 22) , PET was the only modality to demonstrate tumor remnants. One patient (#7) was suitable for re-resection which was performed 48 h after the first surgery. Histopathology confirmed vital tumor tissue exactly at the spot of maximum [
18 F]FET-PET uptake (Fig 2) . All other lesions detected by [ 18 F]FET-PET could not be re-resected due to tumor localization and were followed-up. After three months, recurrence exactly at the site of initial tracer accumulation in post-operative PET was detected in three of the five patients (#16, 18, 22; Fig 3) . All patients underwent radiation therapy. The remaining patient (#21) died three months after surgery. Table 2 gives an overview over the imaging results of the individual patients. [14, [20] [21] [22] and recurrent disease [15, 23] , the differentiation between radiation necrosis versus tumor recurrence [24] , as well as therapy monitoring (16), this is the first study to investigate the performance of early post-operative [ 18 F]FET-PET.
Our data suggest that PET can detect vital residual tumor tissue with high accuracy. All patients with complete resection were correctly classified by PET, thus proving a high negative predictive value. Interestingly, the rate of complete resections of this series was quite high with 75%, but might be explained by the multi-modality approach prior to surgery as well as beneficial localization of the individual tumors in many cases allowing for unlimited surgical approaches.
Compared to MRI, early post-operative [25] . Our data add evidence on the suitability of early metabolic imaging after glioma surgery. There are limitations of this study. First, image guided tissue sampling would have been necessary to validate whether remnants (either in MRI or PET) were truly tumor tissue, especially for conflicting results in the two post-operative imaging modalities. Second, only a small number of patients were included in this pilot study. Third, the problem of brain shift occurring after surgery cannot be completely excluded thereby complicating analysis of early post-operative imaging. Last, histological work-up did not take into account spatial information to correlate imaging findings with surgery.
To date, MRI is the gold standard of brain imaging. In a large study more than 200 patients with newly diagnosed glioblastoma, subjects with residual contrast-enhancing tumor as revealed by early MRI scans had a shorter median overall survival from the time of surgery as compared to patients without residual tumor (1, 2) . Detection of residual vital tumor is therefore critical. However, MRI is prone to unspecific changes which can occur early after surgery. Additional PET imaging could raise confidence of diagnosis and impact on adjuvant therapy, e.g. tailored radiotherapy, by guiding a potential boost to tumor areas. Furthermore, early knowledge of the post-operative PET status can prove extremely useful in the setting of followup imaging in which the differentiation of true tumor recurrence from pseudo-progression has important therapeutic implications.
In conclusion, early assessment of the resection status in HGG seems to be feasible with 
